I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

CALQUENCE has been used to treat more than 85,000 patients worldwide 9 and is approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma ...

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’ s CALQUENCE ® in combination with venetoclax, with or without ...

CALQUENCE CALQUENCE(acalabrutinib) is a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK).CALQUENCEbinds covalently to BTK, thereby inhibiting its activity. 8 In ...

CALQUENCE plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0 ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax, with or ...

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca&CloseCurlyQuote;s CALQUENCE&circledR;(acalabrutinib) in combination with ...